natalizumab

EMA Accepts Marketing Authorization of Natalizumab Biosimilar for MS

Polpharma Biologics of Amsterdam, Netherlands, an international biotech company, announced that the European Medicines Agency (EMA) accepted a Marketing Authorization Application (MAA) for biosimilar natalizumab, a monoclonal antibody treatment for adults with highly active relapsing-remitting multiple sclerosis (RRMS). Natalizumab is a proposed biosimilar to Tysabri®, and the application was for intravenous administration at the same…

Disease-Modifying Therapies Could Help Protect Patients With MS From COVID-19

Patients with multiple sclerosis (MS) treated with interferon beta-1a (IFN) demonstrated significantly increased humoral responses to the Pfizer mRNA vaccine for COVID-19, according to new study results published in Multiple Sclerosis and Related Disorders. In contrast, patients with MS taking cladribine (CLAD), fingolimod (FTY), and ocrelizumab (OCRE) showed a weakened humoral response. Patients on CLAD,…

Ocular Adverse Events Associated With Multiple Sclerosis Therapies

Several therapies are associated with the development of ocular adverse events in patients with multiple sclerosis (MS), according to a report in Systematic Reviews. Colombian researchers conducted a systematic review of therapies including alemtuzumab (Lemtrada®), amantadine, fingolimod (Gilenya®), steroids, CTLA-4 Ig, estriol, interferon β, natalizumab (Tysabri®), hyperbaric oxygen, rituximab (Rituxan®), siponimod (Mayzent®), teriflunomide (Aubagio®), and…

Natalizumab for MS Most Commonly Associated With Progressive Multifocal Leukoencephalopathy

Natalizumab therapy for multiple sclerosis (MS) is most commonly associated with progressive multifocal leukoencephalopathy (PML), a common comorbidity related to disease-modifying MS therapies. This was found in a new study published in the Journal of Neuroimmunology. Other disease-modifying treatments less commonly associated with PML were fingolimod, dimethyl fumarate, ocrelizumab, and alemtuzumab. No therapeutic agent was found…

RRMS relapse

Natalizumab in RRMS: Results From Phase 3b NOVA Study Reported

Biogen released results from its phase 3b NOVA study, with findings demonstrating the efficacy of an every-6-week dosing regimen of natalizumab (Tysabri®) in patients being treated for relapsing-remitting multiple sclerosis (RRMS). “The NOVA study provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the…

woman taking pill

Treatment Possibilities Updated for Pregnant Women With MS

An updated literature review of the safety of disease modifying treatments (DMTs) in pregnant women with multiple sclerosis (MS) demonstrated that glatiramer acetate (GA) and interferon beta (IFN-β) are safe during pregnancy and breastfeeding. The study also recommends the use of natalizumab until 34 weeks of pregnancy for patients requiring continual treatment. Suggested resumption of…

woman prepares an IV Drip

Home Infusion of Natalizumab Appears Promising for People With MS

A pilot randomized crossover study has found that there was no difference in the safety and efficacy between clinical and home infusions of natalizumab in patients with multiple sclerosis (MS), according to a study published in the Medical Journal of Australia. Natalizumab is an intravenous infusion commonly administered under physician supervision in patients with relapsing-remitting…

Next post in MS News Briefs